Dec 16 (Reuters) - Valeant Pharmaceuticals International Inc (N:VRX) VRX.TO :
* Provides financial guidance update
* Sees FY 2016 adjusted non-GAAP earnings per share $13.25 to $13.75
* Sees FY 2016 revenue $12.5 billion to $12.7 billion
* Sees 2016 total revenue $12.5 - $12.7 billion
* Sees Q4 revenue $2.7 - $2.8 billion
* Sees Q4 adjusted EPS $2.55 -$2.65, previously expected $4.00 - $4.20
* Q4 earnings per share view $3.46, revenue view $3.08 billion -- Thomson
Reuters I/B/E/S
* In 2016, expect to reduce debt by about $2.25 billion, including mandatory
payments and maturities
* Source text for Eikon ID:nPn1T4gNg
* Further company coverage VRX.TO